The United States Patent and Trademark Office (USPTO) has granted patent US12582636B2 to HANMI PHARM. CO., LTD. The patent covers a pharmaceutical composite formulation comprising a proton pump inhibitor in a first layer and an antacid (magnesium hydroxide, magnesium oxide, or a mixture thereof) in a second layer. The filing date for this application was January 22, 2021, and the patent is set to be granted on March 24, 2026.

This patent grant signifies a new intellectual property right for the assignee, potentially impacting market exclusivity for this specific formulation. While this is a patent grant and not a regulatory rule, it is relevant for pharmaceutical companies involved in the development and manufacturing of proton pump inhibitors and antacids. Compliance officers should note this as a development in the competitive landscape for these drug classes. No immediate compliance actions are required by this patent grant itself, but it may influence future product development and market strategies.